Investigating the association between calcification morphology descriptors (CMDs) and specific clinicopathological factors of DCIS lesions, such as grade, receptor-based surrogate subtypes based on hormone receptors and HER2, and the risk of local DCIS or IBC recurrence could provide clinicians with valuable insights into the likelihood of DCIS progression and lesion aggressiveness. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.